ホーム>>Signaling Pathways>> GPCR/G protein>> Melatonin Receptors>>Ramelteon

Ramelteon (Synonyms: TAK-375)

カタログ番号GC15053

ラメルテオンは強力で選択性の高い MT1/MT2 の経口活性アゴニストであり、Ki 値はそれぞれ 14 および 112 pM です。

Products are for research use only. Not for human use. We do not sell to patients.

Ramelteon 化学構造

Cas No.: 196597-26-9

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$29.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Ramelteon, a chronohypnotic, is an orally active and highly selective melatonin receptor (MT1, MT2 and MT3) agonist that preferentially binds to MT1 and MT2 receptors leading to potent inhibition of cAMP production in human cells expressing MT1 or MT2 receptors with the half maximal inhibition concentration IC50 values of 21.2 pM/L and 53.4 pM/L respectively [1].

The s-configuration and ether group in the chemical structure of ramelteon confer its high affinity towards MT1 and MT2 receptors with the dissociation constant Ki values of 14 pM and 112 pM respectively in comparison with that of 2650 nM for MT3 receptors [1].

Ramelteon has been found to potently promote sleep without causing any significant adverse effects leading to its application for the treatment of insomnia [1].

References:
[1] Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x.

レビュー

Review for Ramelteon

Average Rating: 5 ★★★★★ (Based on Reviews and 14 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ramelteon

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.